DK1295611T3 - Oligonukleotid-transformerende forbindelser - Google Patents

Oligonukleotid-transformerende forbindelser

Info

Publication number
DK1295611T3
DK1295611T3 DK01938732.3T DK01938732T DK1295611T3 DK 1295611 T3 DK1295611 T3 DK 1295611T3 DK 01938732 T DK01938732 T DK 01938732T DK 1295611 T3 DK1295611 T3 DK 1295611T3
Authority
DK
Denmark
Prior art keywords
oligonucleotide
transforming compounds
transforming
compounds
collagen
Prior art date
Application number
DK01938732.3T
Other languages
English (en)
Inventor
Shunichiro Kubota
Takahiro Ochiya
Hiroshi Itoh
Masayasu Furuse
Shunji Nagahara
Masaaki Terada
Akihiko Sano
Original Assignee
Dainippon Sumitomo Pharma Co
Koken Kk
Nat Cancer Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Sumitomo Pharma Co, Koken Kk, Nat Cancer Ct filed Critical Dainippon Sumitomo Pharma Co
Application granted granted Critical
Publication of DK1295611T3 publication Critical patent/DK1295611T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
DK01938732.3T 2000-06-20 2001-06-19 Oligonukleotid-transformerende forbindelser DK1295611T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000184502 2000-06-20
PCT/JP2001/005195 WO2001097857A1 (fr) 2000-06-20 2001-06-19 Preparations destinees au transfert d'oligonucleotides

Publications (1)

Publication Number Publication Date
DK1295611T3 true DK1295611T3 (da) 2010-10-04

Family

ID=18684937

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01938732.3T DK1295611T3 (da) 2000-06-20 2001-06-19 Oligonukleotid-transformerende forbindelser

Country Status (10)

Country Link
US (3) US20040052840A1 (da)
EP (1) EP1295611B1 (da)
JP (1) JP5118285B2 (da)
AT (1) ATE478688T1 (da)
AU (1) AU2001264317A1 (da)
DE (1) DE60142899D1 (da)
DK (1) DK1295611T3 (da)
ES (1) ES2349137T3 (da)
PT (1) PT1295611E (da)
WO (1) WO2001097857A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW586934B (en) * 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
DK1295611T3 (da) * 2000-06-20 2010-10-04 Dainippon Sumitomo Pharma Co Oligonukleotid-transformerende forbindelser
DE60232149D1 (de) 2001-06-20 2009-06-10 Dainippon Sumitomo Pharma Co Verfahren zur förderung des nukleinsäuretransfers
US20100104631A1 (en) * 2001-08-13 2010-04-29 Lipella Pharmaceuticals Inc. Method of treatment for bladder dysfunction
JPWO2004026343A1 (ja) * 2002-09-20 2006-01-12 住友製薬株式会社 部位特異的遺伝子変換促進剤および遺伝子疾患治療剤
WO2005061717A1 (ja) * 2003-12-19 2005-07-07 Dainippon Sumitomo Pharma Co., Ltd. 新規な核酸導入法
US20090062184A1 (en) * 2005-03-24 2009-03-05 Dainippon Sumitomo Pharma Co., Ltd. Fine particulate preparation comprising complex of nucleic acid molecule and collagen
US7838502B2 (en) * 2005-05-06 2010-11-23 University Of Massachusetts Medical School Compositions and methods to modulate H. influenzae pathogenesis
US20090047319A1 (en) * 2005-05-25 2009-02-19 Kenji Kadomatsu Pharmaceutical composition for obstructive vascular disease
KR100777249B1 (ko) 2006-02-14 2007-11-28 (주)바이오니아 건조 올리고뉴클레오티드 조성물 및 이의 제조 방법
WO2010078403A2 (en) * 2008-12-30 2010-07-08 Lipella Pharmaceuticals Inc. Methods and compositions for diagnosing urological disorders
FR3066115B1 (fr) * 2017-05-10 2019-06-28 Universite de Bordeaux Comprimes de vecteurs d'acides nucleiques

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5115094B2 (da) * 1972-11-01 1976-05-14
US5069936A (en) * 1987-06-25 1991-12-03 Yen Richard C K Manufacturing protein microspheres
US5078997A (en) * 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5098890A (en) * 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5614587A (en) * 1988-11-21 1997-03-25 Collagen Corporation Collagen-based bioadhesive compositions
US5936035A (en) * 1988-11-21 1999-08-10 Cohesion Technologies, Inc. Biocompatible adhesive compositions
JP3187410B2 (ja) * 1989-08-10 2001-07-11 住友製薬株式会社 脳内投与用徐放性製剤
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
FR2694895B1 (fr) * 1992-08-20 1994-11-10 Coletica Procédé de fabrication de microparticules en émulsion par modification de la composition chimique de la phase dispersée après émulsification.
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
CA2163741A1 (en) * 1993-05-28 1994-12-08 Steven Rosenberg Peptide inhibitors of urokinase receptor activity
DK0717617T3 (da) * 1993-09-09 2001-02-05 Schering Ag Mikropartikler indeholdende aktive bestanddele og gas
CA2140053C (en) * 1994-02-09 2000-04-04 Joel S. Rosenblatt Collagen-based injectable drug delivery system and its use
US5942496A (en) * 1994-02-18 1999-08-24 The Regent Of The University Of Michigan Methods and compositions for multiple gene transfer into bone cells
US5583034A (en) * 1994-02-22 1996-12-10 La Jolla Institute For Allergy And Immunology Enhancement of adoptosis using antisense oligonucleotides
US5844107A (en) * 1994-03-23 1998-12-01 Case Western Reserve University Compacted nucleic acids and their delivery to cells
US5563255A (en) * 1994-05-31 1996-10-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
CA2193954A1 (en) * 1994-06-27 1996-01-04 Vu L. Truong Targeted gene delivery system
US6998268B2 (en) * 1995-07-03 2006-02-14 Dainippon Sumitomo Pharma Co. Ltd. Gene preparations
JP3867160B2 (ja) * 1995-07-03 2007-01-10 大日本住友製薬株式会社 遺伝子製剤
CA2225998C (en) * 1995-07-03 2010-11-02 Koken Co., Ltd. Gene preparations containing biocompatible material for sustained release in gene therapy
CA2235685A1 (en) * 1995-10-23 1997-05-01 Hyal Pharmaceutical Australia Limited Hyaluronic acid as dna carrier for gene therapy and vegf antisense dna to treat abnormal retinal vascularization
AU717660B2 (en) * 1995-12-18 2000-03-30 Angiodevice International Gmbh Crosslinked polymer compositions and methods for their use
JP2000506865A (ja) * 1996-03-14 2000-06-06 ジ イミューン リスポンス コーポレイション インターフェロンをコードする遺伝子の標的を定めた送達
US6133437A (en) * 1997-02-13 2000-10-17 Apoptogen, Inc. Modulation of IAPs for the treatment of proliferative diseases
US5874006A (en) * 1996-10-31 1999-02-23 Matrix Pharmaceutical, Inc. Aseptic collagen concentration process
US6042820A (en) * 1996-12-20 2000-03-28 Connaught Laboratories Limited Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
US6218112B1 (en) * 1996-12-23 2001-04-17 Cobra Therapeutics Limited Optimization of gene delivery and gene delivery system
AU747242B2 (en) * 1997-01-08 2002-05-09 Proligo Llc Bioconjugation of macromolecules
US6524613B1 (en) * 1997-04-30 2003-02-25 Regents Of The University Of Minnesota Hepatocellular chimeraplasty
AU2868099A (en) * 1998-02-13 1999-08-30 Selective Genetics, Inc. Concurrent flow mixing methods and apparatuses for the preparation of gene therapy vectors and compositions prepared thereby
CN1173744C (zh) * 1998-05-22 2004-11-03 住友制药株式会社 稳定的基因制剂
EP2363133A1 (en) * 2000-03-31 2011-09-07 Trustees of Boston University Composition comprising DNA fragments and medical and cosmetic uses thereof
DK1295611T3 (da) * 2000-06-20 2010-10-04 Dainippon Sumitomo Pharma Co Oligonukleotid-transformerende forbindelser
JP2002325572A (ja) * 2000-12-25 2002-11-12 Univ Osaka 外来物質の導入方法
DE60232149D1 (de) * 2001-06-20 2009-06-10 Dainippon Sumitomo Pharma Co Verfahren zur förderung des nukleinsäuretransfers
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
WO2004022075A1 (en) * 2002-09-04 2004-03-18 Novartis Ag Treatment of neurological disorders by dsrna adminitration
JPWO2004026343A1 (ja) * 2002-09-20 2006-01-12 住友製薬株式会社 部位特異的遺伝子変換促進剤および遺伝子疾患治療剤
NZ540779A (en) * 2002-11-01 2008-05-30 Univ Pennsylvania Compositions and methods for siRNA inhibition of HIF-1 alpha
ATE477337T1 (de) * 2003-01-16 2010-08-15 Univ Pennsylvania Zusammensetzungen und verfahren zur sirna-hemmung von icam-1
US8227434B1 (en) * 2003-11-04 2012-07-24 H. Lee Moffitt Cancer Center & Research Institute, Inc. Materials and methods for treating oncological disorders
JP4989456B2 (ja) * 2004-02-26 2012-08-01 ベイラー リサーチ インスティテュート 関節炎の全身処置のための組成物および方法
DK1799269T3 (da) * 2004-09-28 2016-10-03 Quark Pharmaceuticals Inc Oligoribonukleotider og fremgangsmåder til anvendelse deraf til behandling af alopeci, akut nyresvigt og andre sygdomme
US8187823B2 (en) * 2004-10-22 2012-05-29 UNIVERSITé LAVAL Modulation of neuroglia-derived BDNF in the treatment and prevention of pain
US7585848B2 (en) * 2005-01-11 2009-09-08 Rush University Medical Center Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc
WO2007082899A1 (en) * 2006-01-17 2007-07-26 Vib Vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
JP5131927B2 (ja) * 2006-06-16 2013-01-30 大正製薬株式会社 Ｒｐｎ２遺伝子発現抑制剤の用途
CA2658550C (en) * 2006-07-21 2018-06-19 Silence Therapeutics Ag Means for inhibiting the expression of protein kinase 3
US7825101B2 (en) * 2006-08-30 2010-11-02 The Board Of Trustees Of The University Of Illinois Modulation of MLCK-L expression and uses thereof
AU2007302803A1 (en) * 2006-10-02 2008-04-10 Aprea Ab RNA interference against Wrap53 to treat hyperproliferative diseases
US7812002B2 (en) * 2007-03-21 2010-10-12 Quark Pharmaceuticals, Inc. Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
EP2507373A4 (en) * 2009-12-04 2013-08-07 Opko Pharmaceuticals Llc COMPOSITIONS AND METHODS FOR INHIBITING VEGF

Also Published As

Publication number Publication date
EP1295611B1 (en) 2010-08-25
US20110028535A1 (en) 2011-02-03
US20090258933A1 (en) 2009-10-15
DE60142899D1 (de) 2010-10-07
AU2001264317A1 (en) 2002-01-02
EP1295611A1 (en) 2003-03-26
US20040052840A1 (en) 2004-03-18
ATE478688T1 (de) 2010-09-15
WO2001097857A1 (fr) 2001-12-27
EP1295611A4 (en) 2009-07-08
JP5118285B2 (ja) 2013-01-16
ES2349137T3 (es) 2010-12-28
PT1295611E (pt) 2010-09-14

Similar Documents

Publication Publication Date Title
PT1459751E (pt) (s,s)-reboxetina para tratar as enxaquecas
EP1190099A4 (en) ANTISENSE MODULATION OF THE P13K P85 EXPRESSION
WO2002036743A3 (en) Antisense modulation of calreticulin expression
ATE263354T1 (de) Vorrichtung zur herstellung von kontaktkörpern
EP1325019A4 (en) ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
AP2210A (en) 4-tetrazolyl-4phenylpiperidine derivatives for treating pain.
MXPA03009645A (es) Proceso para preparar oxazolidinonas.
DK1295611T3 (da) Oligonukleotid-transformerende forbindelser
WO2001029175A3 (en) Antisense modulation of fra-1 expression
AU2180501A (en) Novel DNA polymerase inhibitors, mikanolide and dihydromikanolide
WO2004010956A3 (en) Antisense modulation of lar expression
EP1235924A4 (en) ANTISENSE MODULATION OF KAPPA B NUCLEAR FACTOR RECEPTOR ACTIVATOR (RANK) EXPRESSION
WO2003027229A3 (en) Antisense modulation of rip2 expression
ES1044983Y (es) Aparato de termoestimulacion para tratamientos terapeuticos.
WO2003044167A3 (en) Antisense modulation of human fxr expression
EP1642884A4 (en) PROCESS FOR PREPARING OPTICALLY ACTIVE 1-ALKYL SUBSTITUTED 2,2,2-TRIFLUORETHYLAMINE
WO2002041836A3 (en) Antisense modulation of src-1 expression
WO2004001061A3 (en) Antisense modulation of heme oxygenase 1 expression
IT1311624B1 (it) Apparato per il trattamento di piantagioni in filari.
WO2003033659A3 (en) Antisense modulation of matrix metalloproteinase 1 expression
ES1045858Y (es) Maquina para tratamiento de aceitunas.
WO2002040637A3 (en) Antisense modulation of pi3k p85 expression
WO2002055535A3 (en) Antisense modulation of cytohesin-1 expression
WO2004015126A3 (en) Antisense modulation of edg1 expression
WO2003099204A3 (en) Antisense modulation of inhibitor-kappa b kinase-beta expression